Abzena to build US biologics manufacturing plant in North Carolina
New facility will be research partnering company’s sixth global site and will be dedicated to mammalian biologics
Global research partnering organisation Abzena has announced it will build its new biologics manufacturing site in Sanford, North Carolina, generating around 325 jobs in the area.
The company announced it was adding a sixth global site in January. The new plant – which will cost over $200 million and will be equipped with 12 X 2000L bioreactors -- will be dedicated to cGMP manufacturing capacity for mammalian biologics.
Abzena said the design of the facility has been optimized for phase III and commercial manufacturing of biologics.
As a result of the project’s phased approach to construction, four modular suites will initially come online, each including up to two 2000L bioreactors before two further 2000L suites are added.
Additionally, the site will be equipped to handle existing and new advances in manufacturing such as continuous manufacturing and perfusion. Manufacturing is expected to start in mid-2022.
“We are pleased to provide integrated asset development with a full suite of in-house services from discovery through clinical and commercial phases without the need for technology transfer,” said Jonathan Goldman, CEO of Abzena in a statement.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance